

Swapnil S Potdar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3726100/publications.pdf>

Version: 2024-02-01

22
papers

497
citations

1051969

10
h-index

843174

20
g-index

23
all docs

23
docs citations

23
times ranked

802
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of drug combination effects with a minimal set of experiments. <i>Nature Machine Intelligence</i> , 2019, 1, 568-577.	8.3	99
2	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401.	7.7	73
3	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. <i>Bioinformatics</i> , 2020, 36, 3602-3604.	1.8	68
4	Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma. <i>BMC Cancer</i> , 2019, 19, 628.	1.1	55
5	ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR/PI3K/aurora kinase inhibitors. <i>Journal of Pathology</i> , 2020, 250, 159-169.	2.1	37
6	Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. <i>Leukemia</i> , 2020, 35, 1964-1975.	3.3	35
7	Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. <i>British Journal of Cancer</i> , 2019, 120, 435-443.	2.9	24
8	Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. <i>Clinical and Translational Medicine</i> , 2019, 8, 33.	1.7	20
9	Human Tumor-Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing. <i>Cancers</i> , 2020, 12, 92.	1.7	20
10	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. <i>Oncotarget</i> , 2017, 8, 22606-22615.	0.8	13
11	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 71.	2.3	12
12	Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify <i>Kras</i> -Mutant Lung Cancers. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1863-1874.	1.9	8
13	High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 14755.	1.6	7
14	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2780-2784.	3.3	6
15	Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. <i>Cell Reports Medicine</i> , 2021, 2, 100373.	3.3	6
16	A personalised medicine drug sensitivity and resistance testing platform and utilisation of acoustic droplet ejection at the Institute for Molecular Medicine Finland. <i>Synergy</i> , 2014, 1, 78.	1.1	4
17	Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2022, 6, e701.	1.2	4
18	High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome. <i>Cancers</i> , 2021, 13, 2907.	1.7	3

#	ARTICLE	IF	CITATIONS
19	Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML. Blood, 2018, 132, 2763-2763.	0.6	1
20	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. Blood, 2017, 130, 854-854.	0.6	1
21	A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. Blood, 2014, 124, 3139-3139.	0.6	0
22	Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo. Blood, 2018, 132, 3975-3975.	0.6	0